|
||||||
|
||||||
| |
||||||
| Please click here if this newsletter is not displayed properly! | ||||||
|
The family of P2Y nucleotide receptors are important therapeutic targets including antithrombotic therapy, modulation of the immune system and cardiovascular system, inflammation, pain, diabetes, and treatment of cystic fibrosis and other pulmonary diseases. P2Y receptors are activated by adenine and/or uracil nucleotides. Chemically modified pyrimidine nucleotides like 4-substituted pyrimidine nucleotide analogs are potential agonists of P2Y receptors for pharmacological studies.
Need further information? Please check out our 4-substituted Pyrimidine nucleotides at: http://www.jenabioscience.com/cms/en/1/catalog/1213/ To browse our complete range of products, please refer to www.jenabioscience.com. |
||||||
|
||||||
If you wish not to receive further email newsletters from us, please reply to this E-mail with the subject "UNSUBSCRIBE" or unsubscribe via the form at our website at www.jenabioscience.com.
|
||||||
|
||||||
| Responsible for content / Imprint | ||||||
Jena Bioscience GmbH Loebstedter Str. 80 07749 Jena Germany Phone:+49 – 3641 – 6285 000 Fax: +49 – 3641 – 6285 100 E-Mail: info@jenabioscience.com Register Court: Amtsgericht Jena, HRB 207171 VAT No.: DE 195825742 Managing Directors: Thomas Billert Dr. Mathias Grün |
||||||
| www.jenabioscience.com | ||||||
